Next Article in Journal
An Association Between Possible Sarcopenia as an Early Marker and Mild Cognitive Impairment: A Cross-Sectional Study
Previous Article in Journal
Work–Care Reconciliation Strategies for a Variety of Informal Carers: What Works and What Does Not?
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Public Awareness and Knowledge of Prostate Cancer Screening: A Community Study in Saudi Arabia

1
Department of Clinical Pharmacy, College of Pharmacy, King Khalid University, Abha 62529, Saudi Arabia
2
Department of Pharmacology, College of Pharmacy, King Khalid University, Abha 62529, Saudi Arabia
3
Department of Clinical Pharmacy, College of Pharmacy, Shaqra University, Dawadimi 11961, Saudi Arabia
4
Innova Healthcare, Riyadh 13214, Saudi Arabia
*
Author to whom correspondence should be addressed.
Healthcare 2025, 13(16), 1962; https://doi.org/10.3390/healthcare13161962
Submission received: 11 June 2025 / Revised: 18 July 2025 / Accepted: 6 August 2025 / Published: 11 August 2025

Abstract

Background: Prostate cancer (PCa) is one of the most common malignancies among men in Saudi Arabia and contributes significantly to cancer-related morbidity and mortality. The objective of this survey was to evaluate community awareness and screening practices related to PCa among men in the Asir region of Saudi Arabia. Method: A cross-sectional study was conducted from 5 October to 25 December 2024 among men aged 40 and above in the Asir region, excluding those with a prior PCa diagnosis. Using convenience sampling, 399 participants were recruited via social media and community outreach. Data were collected through a self-administered online questionnaire covering demographics, medical history, PCa knowledge, information sources, prevention, screening awareness, and barriers. Informed consent was obtained from all participants. Results: The study comprised 399 male participants, with 37.09% aged 40–50, 36.34% aged 51–60, and 26.56% over 60. Most participants (363; 90.97%) were married, 245 (61.4%) had a university education, 282 (70.67%) lived in urban areas, and 180 (45.11%) were employed. Over half of the participants, 222 (55.63%), had a personal history of prostate problems. Additionally, 272 (68.17%) had health insurance, and 153 (38.34%) reported a monthly income between 10,000 and 14,999 SAR. The study found that 329 (82.5%) participants had good knowledge of PCa but only 197 (49.4%) had good awareness of screening methods. Key predictors of good awareness of PCa screening included a personal history of prostate problems (odds ratio—OR = 4.791, p = 0.000, confidence interval—CI 2.727–8.418) and health insurance (OR = 0.359, p = 0.000, CI 0.203–0.636). Common barriers to screening were affordability, n = 116 (29.07%), and perceived good health, n = 201 (50.37%). Additionally, 154 participants (38.59%) found screening uncomfortable, while 156 (39.59%) believed the Digital Rectal Exam (DRE) was harmful or embarrassing. Significant differences in perceived barriers were found based on age (F = 11.449, p < 0.001), education (F = 2.608, p = 0.051), occupation (F = 3.668, p = 0.026), family history (F = 17.407, p < 0.001), and income (F = 5.148, p = 0.006). Conclusions: The study highlights a significant gap between general knowledge and specific awareness of prostate cancer (PCa) screening among men in the Asir region. Although 82.5% demonstrated good overall knowledge, only 49.4% were aware of screening methods, and just 44.36% had undergone PSA testing. Common barriers included perceived good health, fear of diagnosis, embarrassment, and financial concerns. However, due to the use of convenience sampling, online distribution, and geographic restriction to the Asir region, the findings may not be generalizable to the broader male population in Saudi Arabia, particularly older men and those in rural areas. Addressing these gaps requires targeted education, empowerment of healthcare providers, and coordinated public health strategies to enhance early detection and reduce the PCa burden.

1. Introduction

Prostate cancer (PCa) is a significant global health issue and one of the most frequently diagnosed cancers in men, with approximately 1.3 million new cases reported worldwide in 2018 [1,2]. The incidence is notably higher in developed countries, largely due to the widespread use of prostate-specific antigen (PSA) testing [3]. The global burden is projected to rise to 1.7 million new cases and 500,000 deaths by 2030 [4]. In the Arab world, both incidence and mortality are increasing, with more patients presenting at advanced stages compared to Western countries like the United States [5,6].
In Saudi Arabia, PCa is the second most common malignancy among men over 60 years, with an age-standardized incidence rate of 5.1 per 100,000 males recorded between 2001 and 2008 [7]. Despite this, awareness and screening remain suboptimal. International guidelines recommend early detection through PSA testing and digital rectal examination (DRE), especially in high-risk groups such as men with a family history or germline mutations. For instance, the American Urological Association suggests initiating screening between the ages of 40 and 45 for high-risk individuals [8,9]. Early detection, particularly of low-grade PCa, has been shown to significantly improve prognosis and survival [10]. The European Randomized Study of Screening for Prostate Cancer (ERSPC) demonstrated reduced mortality through PSA-based screening [11], while the American Cancer Society underscores the need for informed screening decisions [12].
The national cancer registry data ranked PCa as the fourth most frequent cancer among Saudi men in 2014, with 323 new cases and an incidence rate of 5.5 per 100,000. Higher rates were observed in the Eastern Province (12.6) and Riyadh (9.5), with an average diagnosis age of 73 years [13]. A national review also reported an eightfold increase in incidence from 1990 to 2016 [14]. In the Asir region specifically, Otifi et al. found an 8.7% prevalence among 883 patients between 2008 and 2018 [15]. Despite rising trends, PCa remains underdiagnosed due to limited awareness of risk factors, symptoms, and available screening options. This gap can result in delayed diagnosis and poorer health outcomes. Assessing knowledge and behaviors around PCa screening is thus essential to guide public health efforts.
The Asir region in southwestern Saudi Arabia, home to over two million people, comprises both urban and rural populations across challenging mountainous terrain [16]. Although national campaigns by the Saudi Ministry of Health aim to improve cancer awareness and screening, disparities persist, particularly in peripheral and rural communities. Cultural beliefs, limited access to specialist care, and fewer screening facilities may contribute to low awareness and late detection in this region.
Notably, the Asir region remains under-represented in public health research on PCa. Understanding community perceptions and practices is critical for identifying knowledge gaps and developing targeted education strategies. Therefore, this study aims to evaluate awareness, knowledge, and screening behaviors related to prostate cancer among men in the Asir region of Saudi Arabia.

2. Method

2.1. Study Design/Inclusion and Exclusion Criteria

A cross-sectional study was conducted from 5 October to 25 December 2024 among men aged 40 and above residing in the Asir region of Saudi Arabia. Those with a prior diagnosis of prostate cancer or who declined to provide informed consent were excluded.

2.2. Sampling Procedure and Sample Size

Study participants were selected using a non-probability snowball sampling method, which is particularly effective for reaching dispersed or hard-to-access populations. To ensure diversity in participant characteristics, the snowball sampling strategy began with a carefully selected group of initial participants (“seeds”) who represented a range of demographic profiles, including variations in age, educational background, occupation, and geographic location within the Asir region. These initial participants were encouraged to disseminate the survey within their own social and professional circles. This approach was designed to promote wider outreach and facilitate the inclusion of individuals from both urban and rural areas, enhancing the demographic representativeness of the sample.
Prior to the commencement of the study, the total male population of the Asir region (371,290) was considered to calculate the required sample size. The calculation was performed using the Raosoft sample size calculator [17], which is based on Cochran’s formula, applying standard parameters for cross-sectional surveys: a 95% confidence level, 5% margin of error, and an anticipated response distribution of 50%. This 50% prevalence was chosen as a conservative estimate to maximize sample size in the absence of prior data on prostate cancer screening awareness. Based on these parameters, the minimum estimated sample size was 384 participants. A total of 425 responses were received; however, 26 were excluded: 8 due to incomplete forms and 18 due to lack of consent. Therefore, 399 participants were included in the final analysis, exceeding the minimum required sample size (Figure 1).

2.3. Participant Recruitment Process

Initial participants were identified through personal networks, including friends, colleagues, and members of community organizations focused on men’s health. The questionnaire was prepared using Google Forms, and the survey link was then shared via various social media platforms, including Twitter and WhatsApp, as well as through community care centers. To promote inclusivity and broaden participation, the survey was made available in Arabic, the native language of the majority of the population in Saudi Arabia, and was disseminated through community leaders and healthcare professionals across the Asir region. This collaborative approach enabled outreach to individuals from diverse demographic backgrounds varying in age, education level, and socioeconomic status, thereby enhancing the representativeness of the sample. Written informed consent was obtained from all participants before data collection commenced. An informed consent form, detailing the study’s objectives, was provided at the beginning of the questionnaire. Participants who consented were then directed to proceed to the next section. They were assured that participation was voluntary and anonymous and that all personal information would remain confidential and be processed anonymously.
Figure 1. Flow chart illustrating the sampling procedure and participant inclusion process.
Figure 1. Flow chart illustrating the sampling procedure and participant inclusion process.
Healthcare 13 01962 g001

2.4. Data Collection Tool and Questionnaire Validation

A self-administered, structured questionnaire consisting of four main sections was used to collect data. The questionnaire was adapted from previously published research studies [18,19,20]. Initially written in English, it was subsequently translated into Arabic, the native language of the majority of the population in Saudi Arabia. A native Arabic speaker with subject-matter expertise conducted the translation to ensure both linguistic accuracy and cultural relevance.
Prior to the main study, a pilot study involving 50 men from the target population was conducted to evaluate the clarity, language, cultural relevance, and comprehensibility of the questionnaire. Feedback obtained from this pilot testing was instrumental in refining the questionnaire to ensure that all questions and instructions were clearly understood and consistently interpreted by the participants. Participants involved in the pilot study reported that the questionnaire was easy to understand, with no significant ambiguities or misinterpretations, confirming its appropriateness for the target population. This process enhanced the overall robustness and validity of the data collection tool. Additionally, a panel of experts reviewed the format and content of the questionnaire to assess its overall content validity. The reliability of the questionnaire was assessed using Cronbach’s alpha, which yielded values of 0.72 for the knowledge section, 0.83 for awareness, and 0.84 for barriers, indicating satisfactory to good internal consistency.

2.5. Questionnaire Description

The survey questionnaire gathered information on socioeconomic status, personal and family medical history of PCa, knowledge of PCa, sources of information, prevention strategies, awareness of PCa screening techniques, and barriers to screening.
Part 1: The socioeconomic portion covered the following topics: age, marital status, education level, place of residence, employment, history of prostate problems, family history of prostate problems, health insurance status, and monthly family income.
Part 2: Respondents’ knowledge was evaluated through seven questions covering the risk factors around, symptoms of, and prevention of PCa.
Part 3: Awareness of PCa screening methods includes eight statements, such as the various examinations available for cancer detection, the fact that early screening can enhance survival rates, personal experiences with PSA tests, and the frequency of such tests. It also addressed whether only men with urinary symptoms should be screened, the significance of regular prostate examinations, and whether individuals have performed these examinations themselves.
Part 4: Barriers to prostate cancer (PCa) screening were assessed using a 4-point Likert scale across 10 items. Each item represented a potential barrier, including the inability to afford screening, the belief that one is healthy, uncertainty about where to go for screening, fear of discovering a health problem, the perception that PCa screening is time-consuming, concerns about discomfort during the procedure, embarrassment or fear related to the digital rectal exam (DRE), fear of potential impotence, the belief that nothing can prevent PCa, and the belief that PCa is not a serious disease. Responses were rated as 1 = strongly disagree, 2 = disagree, 3 = agree, and 4 = strongly agree. The individual scores from each item were summed to generate a total barrier score for each participant, with higher scores indicating a greater perceived level of barriers to screening.

2.6. Scorings

Participants received a score of 1 for each correct answer and 0 for each incorrect answer. Operational Definition—Knowledge of Prostate Cancer: A total of 14 points was possible in the knowledge section. Participants with scores ≥ 7 were classified as having “good” knowledge, while those with scores < 7 were classified as having “poor” knowledge. Awareness of Prostate Cancer: The awareness section, which consisted of a maximum of 8 points, categorized participants with scores ≥ 4 as having “good” awareness, while those with scores < 4 were classified as having “poor” awareness [20,21].

2.7. Ethical Considerations

The study’s ethical framework was approved by the Institutional Review Committee at King Khalid University (ECM # 2024-3111). All methods were performed in accordance with the relevant guidelines and regulations. Written consent was obtained from all participants before data collection commenced.

2.8. Data Analysis

Statistical analysis was performed using SPSS Statistics, version 20.0 for Windows. Frequencies and percentages were used to describe the socioeconomic characteristics of the study participants. Multivariate logistic regression analysis assessed significant associations between independent variables (socioeconomic groups) and dependent variables (knowledge and awareness). Additionally, t-tests and ANOVA were conducted to identify differences in barriers across socioeconomic groups, with the significance level set at p < 0.05.

3. Results

A total of 399 male participants were included in the study. As shown in Table 1, the majority were aged 40–60 years, n = 294 (73.4%), and married, 363 (91%). Most participants had a university degree, n = 245 (61.4%), and lived in urban areas, n = 282 (70.7%). A personal history of prostate problems was reported by 222 participants (55.6%) and a paternal family history by 184 (46.1%). Health insurance coverage was reported by 272 participants (68.2%). The largest income group earned 10,000–14,999 SAR, n = 153 (38.3%). A total of 180 participants (45.1%) were employed (Table 1).
As shown in Table 2, good knowledge of prostate cancer (PCa) was found in 329 participants (82.5%), whereas good awareness of screening was present in only 197 (49.4%). The mean knowledge score was 9.47 (median = 10.00; range = 14.00), whereas the mean screening awareness score was 4.57 (median = 4.00; range = 8.00), suggesting that while most participants had a relatively high level of knowledge, their awareness regarding screening methods was comparatively lower. As shown in Table 3, most participants knew what PCa is, n = 335 (83.95%), and believed it to be preventable, n = 300 (75.18%). Key identified risk factors included age over 50, n = 336 (84.21%); family history, n = 287 (71.92%); poor physical activity, n = 272 (68.17%); and smoking, n = 247 (61.9%). Frequently reported symptoms included blood in urine, n = 299 (74.93%), erectile dysfunction, n = 295 (73.93%), and lower back pain, n = 280 (70.17%). The most commonly selected age range for PCa screening was 41–50 years, n = 203 (50.87%). Primary sources of information were healthcare providers, n = 146 (36.59%), mass media, n = 112 (28.07%), and the internet, n = 98 (24.56%).
Table 4 (logistic regression analysis of variables associated with knowledge of prostate cancer among study participants) presents the association between various factors and participants’ knowledge levels. The analysis revealed that participants with a secondary level of education had significantly lower odds of having good knowledge about prostate cancer compared to those with a university-level education (odds ratio [OR] = 0.460, 95% confidence interval [CI]: 0.227–0.933, p = 0.031).
Due to the group size imbalance between secondary and university education levels (n = 81 vs. n = 245) and potential confounding, two models were analyzed: an unadjusted model with education only, and an adjusted model including occupation, income, residence, and health insurance. In the unadjusted model (Table 5), secondary education was significantly associated with lower knowledge (OR = 0.476, 95% CI: 0.258–0.878; p = 0.018). This association remained significant in the adjusted model (Table 6; OR = 0.481; 95% CI: 0.242–0.957; p = 0.037), indicating minimal confounding. While unemployment was also significant (OR = 2.574; 95% CI: 1.084–6.110; p = 0.032), it did not affect the education effect. These results support the robustness of the original model and confirm that secondary education independently predicts lower knowledge of prostate cancer, with no need to alter the model based on moderate group size differences.
Table 7 summarizes key aspects of awareness and uptake of prostate cancer (PCa) screening. A total of 29.3% were unaware of any screening methods, while 76.9% believed early screening improves survival. PSA testing had been undertaken by 44.4%, though 36.3% could not recall. Treatment awareness was limited, with only 29.8% knowing about drugs or chemotherapy.
Table 8 presents logistic regression results identifying significant predictors of PSA test uptake. Unmarried individuals were significantly less likely to undergo testing (OR = 0.274; 95% CI: 0.084–0.898; p = 0.033). Participants with a personal history of prostate problems were over four times more likely to have undergone testing (OR = 4.107; 95% CI: 2.296–7.348; p < 0.001). Lack of health insurance was associated with lower testing rates (OR = 0.428; 95% CI: 0.232–0.790; p = 0.007). A family history of prostate problems through maternal relatives (OR = 4.033; 95% CI: 1.676–9.707; p = 0.002) and fathers (OR = 1.758; 95% CI: 1.017–3.040; p = 0.043) significantly increased the likelihood of testing. Other demographic variables were not statistically significant.
Table 9 presents the logistic regression analysis of variables associated with awareness of prostate cancer screening among the study participants. Logistic regression analysis showed that a personal history of prostate problems was strongly associated with good awareness (OR = 4.791, 95% CI: 2.727–8.418, p < 0.001). Having health insurance also significantly predicted good awareness (OR = 2.786, 95% CI: 1.573–4.935, p < 0.001). Participants with health insurance were nearly 2.8 times more likely to have good awareness compared to those without insurance.
Table 10 indicates that among men without a personal history of prostate problems, awareness of prostate cancer screening was significantly associated with health insurance, occupation, and family history. Participants with health insurance were over twice as likely to be aware of screening (OR = 2.288, 95% CI: 1.025–5.109, p = 0.043), while unemployed individuals had higher awareness compared to retirees (OR = 5.834, 95% CI: 1.332–25.552, p = 0.019). Additionally, those with a paternal family history of prostate problems were more likely to be aware than those with no known history (OR = 2.488, 95% CI: 1.059–5.847, p = 0.037).
Table 11 highlights key barriers to prostate cancer (PCa) screening, revealing that psychological, informational, and financial factors significantly hinder participation. The most commonly cited obstacles were a perceived lack of need due to good health (69.4%), fear of diagnosis (67.7%), and uncertainty about where to go for screening (65.9%). Other notable concerns included the potential negative impact on sexual health (60.4%), discomfort with the procedure (59.4%), embarrassment or harm associated with DRE (58.9%), and financial constraints (57.4%). These findings underscore the need for targeted interventions that address emotional concerns, improve knowledge of screening services, and mitigate cost-related barriers.
Table 12 presents the results of t-tests and ANOVA analyses examining differences in perceived barriers to prostate cancer screening across various demographic and health-related variables. The independent t-tests showed no significant differences in barrier scores based on marital status or residence. However, participants with a personal history of prostate problems reported significantly higher barrier scores (mean = 28.26, SD = 5.94) than those without such a history (mean = 24.79, SD = 5.48; t = 6.011, p < 0.001). Similarly, participants with health insurance had higher barrier scores (mean = 27.71, SD = 5.98) compared to uninsured individuals (mean = 24.59, SD = 5.43; t = 4.998, p < 0.001). A significant difference in barrier scores was observed based on whether participants had undergone PSA testing. Those who had taken the test reported higher barrier scores (M = 28.57, SD = 6.07) than those who had not (M = 25.24, SD = 5.50), with a statistically significant difference (t = 5.733, p < 0.001).
ANOVA revealed significant differences in perceived barriers by age (F = 11.449, p < 0.001; highest in 51–60 years), occupation (F = 3.668, p = 0.026; higher in unemployed), family history (F = 17.407, p < 0.001; highest with maternal history), and income (F = 5.148, p = 0.006; higher in lower-income groups). Education showed a marginal effect (F = 2.608, p = 0.051), suggesting a possible influence on perceived barriers.

4. Discussion

This study assessed awareness and knowledge of prostate cancer (PCa) and its screening among men in the Asir region of Saudi Arabia. While 82.5% of participants reported general awareness of PCa, only 49.4% demonstrated knowledge of appropriate screening methods. This highlights a critical knowledge behavior gap, where awareness does not consistently translate into preventive action, particularly regarding screening methods such as DRE and PSA testing. Compared to previous studies from Jazan, Medina, Jeddah, and Makkah, which reported lower general awareness and limited knowledge of screening modalities [7,22], our findings reflect a relatively higher level of awareness but a similar shortfall in actionable knowledge. For instance, awareness of DRE and PSA testing was only 37.34% and 18.54%, respectively, comparable to findings from Kenya and Tanzania [23,24], and markedly lower than studies reporting awareness levels as high as 90% [25]. This underscores a broader trend across various regions: awareness of PCa exists, but understanding of screening tools remains insufficient, calling for targeted health education initiatives.
Our study adds novel insights by focusing on this knowledge–practice disconnect in a community-based sample from the Asir region, an area previously under-represented in PCa research. Unlike many studies that focus solely on general awareness, our findings provide actionable information relevant for public health planning and screening interventions. Awareness of PCa risk factors such as family history, advanced age, smoking, and physical inactivity was moderate and consistent with findings from Riyadh and international studies [25,26,27,28,29,30]. However, regional disparities persist. For example, although 50% of participants in our study recognized advanced age as a risk factor, lower recognition has been reported in South Africa [24], suggesting that cultural factors and regional health messaging play an important role in shaping public knowledge. Sociodemographic analysis revealed no significant association between income and PCa awareness, consistent with other Saudi studies [31]. This could reflect the impact of Saudi Arabia’s government-sponsored healthcare programs, which may help equalize access to health information. Instead, variables such as educational level, age, and employment status were more predictive of awareness, aligning with global evidence [32,33]. These findings reinforce the importance of tailoring educational interventions to less-educated populations.
Notably, health insurance coverage emerged as a strong predictor of PCa awareness; insured participants were 2.8 times more likely to possess good knowledge. This supports previous findings linking insurance status with better health literacy and screening uptake [19,34,35]. Integrating public health education into insurance-related services could therefore serve as a strategic avenue to improve screening behaviors. Healthcare providers were the most frequently reported source of information (36.59%), followed by media. This pattern contrasts with studies where media dominated [20] and aligns more closely with findings from Rwanda and Ethiopia that emphasize the role of healthcare professionals [19,36]. Given that most participants expressed belief in the benefits of early detection, consistent with earlier studies linking delayed presentation to poor outcomes [37,38], the proactive engagement of healthcare providers is crucial in enhancing PCa education and encouraging timely screening.
Despite the relatively high general awareness, screening uptake remains low, a finding echoed in studies from the U.S., Nigeria, and Cameroon, where knowledge did not reliably lead to preventive behavior [39]. For instance, Ernest et al. [40] found that only 8.1% of respondents underwent screening despite high awareness of symptoms. Similarly, Shaqran et al. [18] reported poor screening behaviors, consistent with our findings. Nevertheless, the awareness levels observed in our study were higher than those reported in Jordan and Egypt [41], suggesting geographic variability in public health education and healthcare access. Participants identified multiple barriers to screening: a perceived lack of need due to good health, fear of diagnosis, embarrassment about DRE, financial concerns, and unawareness of screening locations. These align with barriers documented in sub-Saharan Africa and Turkey, including mistrust, negligence, and logistical issues [20,42,43,44]. Interestingly, we found that perceived barriers were higher among individuals with insurance and a history of prostate issues, possibly reflecting increased awareness without adequate guidance or support to act on it.
To enhance screening uptake, comprehensive and multifaceted strategies are required. Public education campaigns should specifically target middle-aged men, especially those who are asymptomatic to challenge misconceptions and reinforce the value of early detection. Addressing psychological and logistical barriers through mobile clinics, subsidized testing, and clearer access pathways is also critical. Aligning these efforts with international screening guidelines, such as those from the American Cancer Society and the U.S. Preventive Services Task Force [45,46,47], can further bolster national prevention efforts.
It is important to acknowledge that the use of convenience sampling and online distribution may have introduced selection bias. Our sample likely included younger, more educated, and internet-literate individuals residing in urban areas of the Asir region, potentially under-representing older adults, individuals with lower educational attainment, and rural residents. This limitation may have inflated the reported awareness and knowledge levels [48]. Therefore, these findings should be interpreted as representative of the digitally accessible population in Asir rather than the broader Saudi male population. Future research using randomized or stratified sampling across diverse regions will be essential for enhancing generalizability and informing national screening policies.

Limitations

This study has several important limitations that should be acknowledged. First, it employed a non-probability convenience sampling method, with participants recruited primarily via personal networks and social media platforms. This approach likely introduced self-selection bias, potentially over-representing younger, more educated, and health-conscious individuals, while under-representing older, rural, or less-connected populations. Due to the anonymous nature of online recruitment, we were unable to verify whether all participants were indeed adult males residing in the Asir region. Given that the study was limited to a single region and relied on an internet-active cohort, the findings may not be generalizable to the broader Saudi male population. The use of a self-administered, self-reported questionnaire also introduces the possibility of recall and social desirability biases, which may have affected the accuracy of responses. Additionally, the cross-sectional design of the study prevents the establishment of causal relationships. Another key limitation is that the study did not assess actual screening behavior, nor did it apply a behavioral framework to evaluate whether awareness translated into practice. Although we identified predictors of awareness, we did not explore whether this knowledge led to participation in screening activities. To enhance transparency and interpretation, we recommend that the abstract and conclusion clearly state that these findings primarily reflect the awareness levels of the younger, internet-active male population in the Asir region. If feasible, future analyses should examine subgroup differences—for example, comparing awareness between age groups—to illustrate how the sampling method may have influenced the results. Future studies should adopt more representative, randomized sampling strategies, include participants from both urban and rural areas, and expand data collection across multiple regions in Saudi Arabia. Incorporating validated behavioral models would also help elucidate the relationship between awareness and actual screening uptake. Until such data are available, caution is warranted in generalizing these findings to the broader population.

5. Conclusions

This study highlights a significant gap between general awareness and specific knowledge of prostate cancer (PCa) screening methods among men in the Asir region of Saudi Arabia. Although 82.5% of participants demonstrated good overall knowledge, less than half (49.4%) were aware of key screening tools such as the prostate-specific antigen (PSA) test and digital rectal examination (DRE), and only 44.36% had undergone PSA testing. Multivariable analysis identified statistically significant associations between screening awareness and factors such as health insurance status, marital status, and personal or family history of prostate issues. However, due to the study’s cross-sectional nature, no causal relationships can be inferred. Participants also reported several perceived barriers to screening, including good self-reported health, fear of diagnosis, embarrassment, discomfort, and financial concerns.
These findings should be interpreted with caution due to several limitations. The study employed a convenience sampling strategy and online survey format, with data collected only from the Asir region. This may limit the generalizability of results, particularly to older adults, rural populations, and individuals without internet access. Furthermore, the cross-sectional design precludes the establishment of temporal or causal relationships. To address these gaps, health authorities should implement targeted strategies to enhance screening accessibility and public awareness. This includes deploying mobile screening units in underserved areas, integrating PCa screening into primary care settings, and offering subsidized or free PSA testing for low-income and uninsured individuals. Awareness campaigns should be culturally tailored and delivered through mass media, mosques, workplaces, and community centers to reach older and less-educated men. Healthcare providers should be empowered to play a more proactive role in patient education, consistent with national and international screening guidelines. Future efforts should focus on inclusive and culturally tailored educational programs that promote informed decision-making regarding PCa screening in accordance with clinical guidelines. In addition, policymakers should prioritize eliminating psychosocial and structural barriers, such as stigma, fear, and cost, that hinder screening participation. Further research using regionally representative, randomized sampling is needed to better understand prostate cancer awareness and screening behaviors across diverse populations in Saudi Arabia.

Author Contributions

Conceptualization, G.K.; Methodology, G.K., K.O., Y.I.A., E.S., A.M.A. and H.A.A.; Software, G.K.; Validation, K.O. and A.M.A.; Investigation, Y.I.A., E.S. and A.M.A.; Resources, K.O. and H.A.A.; Data curation, G.K., K.O., Y.I.A. and E.S.; Writing—original draft, G.K., Y.I.A., E.S., A.M.A. and H.A.A.; Writing—review & editing, K.O. and A.M.A.; Visualization, G.K., Y.I.A. and E.S.; Supervision, K.O. and A.M.A.; Project administration, Y.I.A., E.S., A.M.A. and H.A.A.; Funding acquisition, G.K., A.M.A. and E.S. All authors have read and agreed to the published version of the manuscript.

Funding

The authors extend their appreciation to the Deanship of Research and Graduate studies at King Khalid University for funding this work through large Research Project under grant number RGP2/44/46.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Review Board of King Khalid University (ECM No 2024-3111) approval date: 29 September 2024).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

The original contributions presented in the study are included in the article. Further inquiries can be directed to the corresponding author.

Acknowledgments

The authors extend their appreciation to the Deanship of Research and Graduate studies at King Khalid University for funding this work.

Conflicts of Interest

Author Hebah Abdullah Alenazi is employed by Innova Healthcare. The company had no involvement in the study design, data collection, analysis, interpretation, or manuscript preparation. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

  1. Ferlay, J.; Colombet, M.; Soerjomataram, I.; Mathers, C.; Parkin, D.M.; Piñeros, M.; Znaor, A.; Bray, F. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int. J. Cancer 2019, 144, 1941–1953. [Google Scholar] [CrossRef]
  2. Rawla, P. Epidemiology of prostate cancer. World J. Oncol. 2019, 10, 63–89. [Google Scholar] [CrossRef] [PubMed]
  3. Quinn, M.; Babb, P. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: International comparisons. BJU Int. 2002, 90, 162–173. [Google Scholar] [CrossRef] [PubMed]
  4. Ferlay, J.; Shin, H.R.; Bray, F.; Forman, D.; Mathers, C.; Parkin, D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 2010, 127, 2893–2917. [Google Scholar] [CrossRef] [PubMed]
  5. All cancers estimated incidence, mortality and prevalence of all cancers (excluding non-melanoma skin cancer) in 2012. J. Natl. Cancer Inst. 2017, 109, 9. [CrossRef]
  6. Osman, E.; Gomha, M.A.; Harb, A.; Aldayel, A.; Aloraifi, I.; Almousa, R.; Khan, I. An early-detection programme for prostate cancer in Saudi men: A call from a tertiary-care centre in the Eastern province. Arab. J. Urol. 2014, 12, 187–191. [Google Scholar] [CrossRef]
  7. Jarb, A.F.; Aljuaid, A.K.; Alghamdi, S.M.; Almathami, A.A.; Altawili, A.A.; Alesawi, A. Awareness about prostate cancer and its screening in Medina, Jeddah, and Makkah, Saudi Arabia population. Urol. Ann. 2022, 14, 27–32. [Google Scholar] [CrossRef]
  8. Wei, J.T.; Barocas, D.; Carlsson, S.; Coakley, F.; Eggener, S.; Etzioni, R.; Fine, S.W.; Han, M.; Kim, S.K.; Kirkby, E.; et al. Early detection of prostate cancer: AUA/SUO guideline part I: Prostate cancer screening. J. Urol. 2023, 210, 45–53. [Google Scholar] [CrossRef]
  9. Garraway, I.; Pienta, K.J.; Prostate Cancer Foundation. Prostate Cancer Screening Guidelines for Black Men in the United States. NEJM Evid. 2024, 3, EVIDoa2300289. [Google Scholar] [CrossRef]
  10. Schröder, F.H.; Hugosson, J.; Roobol-Bouts, M.J.; Tammela, T.L.J.; Ciatto, S.; Nelen, V.; Kwiatkowski, M.; Lujan, M.; Lilja, H.; Zappa, M.; et al. Screening and prostate-cancer mortality in a randomized European study. N. Engl. J. Med. 2009, 360, 1320–1328. [Google Scholar] [CrossRef]
  11. Release, P. International agency for research on cancer. Asian Pac. J. Cancer Prev. 2003, 4, 3–4. [Google Scholar]
  12. Pinsky, P.F.; Prorok, P.C.; Yu, K.; Kramer, B.S.; Black, A.; Gohagan, J.K.; Andriole, G.L. Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years. Cancer 2017, 123, 592–599. [Google Scholar] [CrossRef]
  13. Wolf, A.M.; Wender, R.C.; Etzioni, R.B.; Thompson, I.M.; D'Amico, A.V.; Volk, R.J.; Smith, R.A. American Cancer Society guideline for the early detection of prostate cancer: Update 2010. CA Cancer J. Clin. 2010, 60, 70–98. [Google Scholar] [CrossRef]
  14. Al-Eid, H.S.; Bazarbashi, S. Cancer Incidence Report Saudi Arabia 2010 Saudi Cancer Registry. Available online: https://shc.gov.sa/Arabic/NewNCC/Activities/AnnualReports/2010.pdf (accessed on 2 November 2024).
  15. Otifi, H.M.; Abdul-Wahab, O.M.S.; Al-Shyarba, M.H.; Al Fayi, M.S.S.; Al Murea, A.H.; Yacoub, E. Clinicopathological features and prevalence of prostate cancer in Aseer, Saudi Arabia. Saudi Med. J. 2022, 43, 755–759. [Google Scholar] [CrossRef] [PubMed]
  16. General Authority for Statistics. Population by Administrative Region. Saudi Arabia. 2022. Available online: https://www.stats.gov.sa (accessed on 2 November 2024).
  17. Sample Size Calculator. Raosoft, Inc. (Online). Available online: http://www.raosoft.com/samplesize.html (accessed on 20 August 2024).
  18. Shaqran, T.M.; Alanazi, R.M.; Haider, A.M.; Almohammadi, A.D.; Hawsawi, H.A.; Almehmadi, S.G.; Alanaze, T.B.; Al-Qahtani, M.Y.; Alshammari, K.F. Knowledge and Awareness of Screening for Prostate Cancer Risk Factors and Symptoms Among the General Population in Tabuk City, Saudi Arabia. Cureus 2023, 15, e46472. [Google Scholar] [CrossRef] [PubMed]
  19. Benurugo, G.; Munyambaraga, E.; Chironda, G.; Bisanukuri, E. Awareness on prostate cancer and screening practices among men attending outpatient at a referral hospital in Kigali, Rwanda: A quantitative study. Int. J. Afr. Nurs. Sci. 2020, 13, 100241. [Google Scholar] [CrossRef]
  20. Ngowi, B.N.; Mremi, A.; Mbwambo, O.J.; Mitao, M.P.; Nyindo, M.; Mteta, K.A.; Mmbaga, B.T. Prostate cancer knowledge and barriers to screening among men at risk in northern Tanzania: A community-based study. Cancer Treat. Res. Commun. 2024, 39, 100811. [Google Scholar] [CrossRef]
  21. Mbugua, R.G.; Oluchina, S.; Karanja, S. Prostate cancer awareness and screening among men in a rural community in Kenya: A cross-sectional study. Afr J. Urol. 2021, 27, 7. [Google Scholar] [CrossRef]
  22. Elyas, A.; Mahfouz, M.S.; Suwaydi, A.Z.A.; Alotayf, O.A.; Tayri, A.O.; Daghriri, B.F.; Daghreeri, A.A.; Hattan, F.A.; Akkam, M.M. Prostate Cancer Knowledge and Attitude Toward Screening Practices Among Men 40 and Over in the Jazan Region, Saudi Arabia. J. Cancer Epidemiol. 2024, 2024, 2713372. [Google Scholar] [CrossRef]
  23. Bugoye, F.C.; Leyna, G.H.; Moen, K.; Mmbaga, E.J. Knowledge, perceived risk and utilization of prostate cancer screening services among men in Dar Es Salaam, Tanzania. Prostate Cancer 2019, 2019, 2463048. [Google Scholar] [CrossRef]
  24. Maladze, N.; Maphula, A.; Maluleke, M.; Makhado, L. Knowledge and attitudes towards prostate cancer and screening among males in limpopo province, South Africa. Int. J. Environ. Res. Public Health 2023, 20, 5220. [Google Scholar] [CrossRef]
  25. Alqudah, M.A.Y.; Al-Samman, R.; Matalgah, O.; Abu Farhah, R. Early detection of prostate cancer: Self-reported knowledge and attitude of physicians in Jordan. INQUIRY J. Health Care Organ. Provis. Financ. 2022, 59, 00469580221095822. [Google Scholar] [CrossRef]
  26. Farhat, K.H.; Arafa, M.; Rabah, D.M. Knowledge and attitude of the population toward cancer prostate Riyadh, Saudi Arabia. Urol. Ann. 2015, 7, 154–158. [Google Scholar] [CrossRef]
  27. Yeboah-Asiamah, B.; Yirenya-Tawiah, D.; Baafi, D.; Ackumey, M. Perceptions and knowledge about prostate cancer and attitudes towards prostate cancer screening among male teachers in the Sunyani Municipality, Ghana. Afr. J. Urol. 2017, 23, 184–191. [Google Scholar] [CrossRef]
  28. Makungu, M.L.; Mweya, C.N. Assessing knowledge, attitude and practice towards prostate cancer screening among males in Southwest Tanzania: A cross-sectional study. Cancer Treat. Res. Commun. 2023, 36, 100716. [Google Scholar] [CrossRef]
  29. Nakandi, H.; Kirabo, M.; Semugabo, C.; Kittengo, A.; Kitayimbwa, P.; Kalungi, S.; Maena, J. Knowledge, attitudes and practices of Ugandan men regarding prostate cancer. Afr. J. Urol. 2 2013, 19, 165–170. [Google Scholar] [CrossRef]
  30. Alothman, A.M.; Altamimi, A.F.; Alhenaki, A.W.; Almansour, N.M.; Alhusaini, A.K.; Alateeq, F. The knowledge and attitude towards prostate cancer and screening practices among males in Saudi Arabia. J. Fam. Med. Prim. Care 2022, 6, 169–170. [Google Scholar] [CrossRef]
  31. Madkhali, M.A.; Alhazmi, E.; Hakami, F.; Darraj, H.; Hamdi, S.; Hakami, K.M.; Gadi, W.H.; Sharahily, R.M.; Hufaysi, A.H.; Alhazmi, L.; et al. A Cross-Sectional Study on the Knowledge and Awareness of Lung Cancer and Screening in Jazan Region, Saudi Arabia. J. Multidiscip. Health 2023, 16, 3857–3870. [Google Scholar] [CrossRef]
  32. Viswanath, K.; Finnegan, J.R. The knowledge gap hypothesis: Twenty-five years later. Ann. Int. Commun. Assoc. 1996, 19, 187–228. [Google Scholar] [CrossRef]
  33. Chen, L.; Kaphingst, K. Risk perceptions and family history of lung cancer: Differences by smoking status. Public Health Genom. 2011, 14, 26–34. [Google Scholar] [CrossRef]
  34. Dawkins, B.; Renwick, C.; Ensor, T.; Shinkins, B.; Jayne, D.; Meads, D. What factors affect patients’ ability to access healthcare? An overview of systematic reviews. Trop. Med. Int. Health 2021, 26, 1177–1188. [Google Scholar] [CrossRef]
  35. Erena, A.N.; Shen, G.; Lei, P. Prostate cancer awareness and screening practice among Kenyan men. Eur. J. Cancer Prev. 2020, 29, 252–258. [Google Scholar] [CrossRef] [PubMed]
  36. Gebru, T.; Mekonnen, H.; Getahun, N.; Meseret, F.; Masrie, A.; Mandefro, M.; Shawel, S.; Tamire, A.; Berhanu, A.; Birhanu, A. Awareness of prostate cancer and its associated factors among male patients attending care in the urology unit at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia. BMJ Open 2023, 13, e073602. [Google Scholar] [CrossRef] [PubMed]
  37. Ekwere, P.D.; Egbe, S.N. The Changing Pattern of Prostate Cancer in Nigerians: Current Status in Southeastern States. J. Natl. Med. Assoc. 2022, 94, 619–627. [Google Scholar]
  38. Eke, N.; Sapira, M.K. Prostate Cancer in Port Harcourt, Nigeria: Features and Outcome. Niger. J. Surg. Res. 2022, 4, 33–44. [Google Scholar] [CrossRef]
  39. Ogunsanya, M. Perceived Behavioral Control regarding Prostate Cancer Screening among Black Men in West Africa and the United States. Cancer Health Disparities 2019, 4, e1–e17. [Google Scholar]
  40. Ernest, K.; Saleh, R.; Fran, C.; Rodrigue, P.; Matthew, D.; Oghenekome, O. Prostate cancer screening knowledge, attitudes, and beliefs among men in Bamenda, Cameroon. Int. J. Public Health Epidemiol. 2017, 6, 339–349. [Google Scholar]
  41. Arafa, M.A.; Rabah, D.M.; Wahdan, I.H. Awareness of general public towards cancer prostate and screening practice in Arabic communities: A comparative multi-center study. Asian Pac J Cancer Prev. 2012, 13, 4321–4326. [Google Scholar] [CrossRef]
  42. Baratedi, W.M.; Tshiamo, W.B.; Mogobe, K.D. Barriers to prostate cancer screening by men in sub-Saharan Africa: An integrated review. J. Nurs. Sch. 2020, 52, 85–94. [Google Scholar] [CrossRef]
  43. Turkan, S.; Doğan, F.; Ekmekçioğlu, O.; Çolak, A.; Kalkan, M.; Şahin, Ç. The level of knowledge and awareness about prostate cancer in the Turkish male and the relevant effective factors. Turk. Urol. Derg. 2016, 42, 134–139. [Google Scholar] [CrossRef]
  44. Carter, H.B. American Urological Association (AUA) guideline on prostate cancer detection: Process and rationale. BJU Int. 2013, 112, 543–547. [Google Scholar] [CrossRef]
  45. Brawley, O.W.; Gansler, T. Introducing the 2010 American Cancer Society prostate cancer screening guideline. CA Cancer J. Clin. 2010, 60, 68–69. [Google Scholar] [CrossRef]
  46. Grossman, D.C.; Curry, S.J.; Owens, D.K.; Bibbins-Domingo, K.; Caughey, A.B.; Davidson, K.W.; US Preventive Services Task Force. Screening for prostate cancer: US preventive services task force recommendation statement. JAMA 2018, 319, 1901–1913. [Google Scholar] [CrossRef]
  47. Bethlehem, J. Selection bias in web surveys. Int. Stat. Rev. 2010, 78, 161–188. [Google Scholar] [CrossRef]
  48. Fricker, R.D. Sampling methods for web and e-mail surveys. In The SAGE Handbook of Online Research Methods; Fielding, N., Lee, R.M., Blank, G., Eds.; SAGE Publications: London, UK, 2008; pp. 195–216. [Google Scholar]
Table 1. Distribution of demographic, health, and socioeconomic factors among study participants.
Table 1. Distribution of demographic, health, and socioeconomic factors among study participants.
VariablesCategoryNumber (n = 399) (%)
Age40–50148 (37.09)
51–60145 (36.34)
Above 60 years106 (26.56)
Marital statusYes363 (90.97)
No36 (9.02)
Level of educationPrimary level12 (3)
Secondary level81(20.3)
University level245 (61.4)
Other (uneducated)61(15.28)
ResidenceRural117 (29.32)
City282 (70.67)
OccupationEmployed180 (45.11)
Unemployed122 (30.57)
Retired97 (24.31)
Personal history of prostate problemsYes222 (55.63)
No177 (44.36)
Family history of prostate problemsMother’s relative40 (10)
From father184 (46.11)
Not known175 (43.85)
Health insuranceYes272 (68.17)
No127 (31.82)
Monthly family income5000 to 9999 SAR130 (32.58)
10,000 to 14,999 SAR153 (38.34)
Above 15,000 SAR116 (29.07)
Table 2. Descriptive statistics and categorization of knowledge and awareness scores related to prostate cancer screening among the study population.
Table 2. Descriptive statistics and categorization of knowledge and awareness scores related to prostate cancer screening among the study population.
ScoresKnowledge (%) (n = 399)Awareness of Screening (n = 399) (%)
Good329 (82.5)197 (49.4)
Poor70 (17.5)202 (50.6)
Mean9.474.57
Median10.004.00
Range14.008.00
Table 3. Knowledge and sources of information regarding prostate cancer among study participants.
Table 3. Knowledge and sources of information regarding prostate cancer among study participants.
Knowledge QuestionsYes (%)No (%)
Do you know what prostate cancer is?335 (83.95)64 (16.04)
Is it possible to prevent prostate cancer?300 (75.18)99 (24.81)
Have you ever heard about prostate-specific antigen (PSA)?210 (52.63)189 (47.36)
Prostate cancer risk factors
Increased age > 50 years336 (84.21)63 (15.78)
Family history287 (71.92)112 (28.07)
Poor physical activity272 (68.17)127 (31.82)
Smoking247 (61.9)152 (38.09)
Prostate cancer symptoms
Difficulty in urine emission241 (60.4)158 (39.59)
Erectile dysfunction295 (73.93)104 (26.06)
Lower back pain280 (70.17)119 (29.82)
Lower pelvic pain262 (65.66)137 (34.33)
Blood in urine299 (74.93)100 (25.06)
In your view, at what age should men start to be more concerned about getting the examination?
30 to 40 years74 (18.54)
41 to 50 years203 (50.87)
Above 51 years122 (30.57)
Effective resources of obtaining information about prostate cancer
Health providers146 (36.59)
Mass media112 (28.07)
Internet98 (24.56)
Colleagues43 (10.77)
Table 4. Logistic regression analysis of variables associated with knowledge of prostate cancer among study participants.
Table 4. Logistic regression analysis of variables associated with knowledge of prostate cancer among study participants.
Independent VariablesGroupsB ValueStd. ErrorWaldp ValueOR95% Confidence Interval (CI)
Intercept1.6040.39716.3280.000
Age rangesAbove 60 years−0.1300.5210.063p = 0.8030.8780.316–2.439
51–60 years0.1780.3700.231p = 0.6311.1950.578–2.468
40–50 yearsReference
Marital statusNo−0.3250.4420.540p = 0.4620.7220.304–1.719
Yes
Personal history of prostate problemsYes0.1720.3530.238p = 0.6261.1880.595–2.371
NoReference
Health insuranceNo−0.1390.3320.175p = 0.6750.8700.453–1.669
YesReference
Level of educationPrimary level0.0770.9080.007p = 0.9331.0800.182–6.397
Secondary level−0.7760.3604.635p = 0.031 *0.4600.227–0.933
Other (uneducated)−0.6270.5721.199p = 0.2730.5340.174–1.641
University levelReference
ResidenceRural−0.5500.3872.026p = 0.1550.5770.270–1.231
CityReference
OccupationRetired−0.0110.3970.001p = 0.9780.9890.454–2.153
Unemployed0.8520.4643.368p = 0.0662.3450.944–5.825
EmployedReference
Family history of prostate problemsMother’s relative0.8520.5942.057p = 0.1522.3450.732–7.519
From father0.4880.3232.286p = 0.1311.6290.865–3.067
Not knownReference
Monthly family income5000 to 9999 SAR−0.1980.3890.260p = 0.6100.8200.383–1.758
10,000 to 14,999 SAR−0.1970.3740.277p = 0.5990.8210.395–1.710
Above 15,000 SARReference
In all the independent variables, the last group is the reference category against which the OR is computed. * p < 0.05 is considered significant. OR—odds ratio; CI—confidence interval; B value—beta value.
Table 5. Logistic regression analysis for knowledge—good [UNADJUSTED MODEL].
Table 5. Logistic regression analysis for knowledge—good [UNADJUSTED MODEL].
Education LevelBSEWaldp-ValueOR95% Confidence Interval (CI)
Primary–0.1820.7960.052p = 0.8190.8330.175–3.965
Secondary–0.7420.3125.639p = 0.018 *0.4760.258–0.878
Uneducated–0.3850.3701.080p = 0.2990.6810.329–1.406
UniversityReference1.000
* p < 0.05 is considered significant. OR—odds ratio; CI—confidence interval; B value—beta value.
Table 6. Logistic regression analysis for knowledge—good [ADJUSTED MODEL].
Table 6. Logistic regression analysis for knowledge—good [ADJUSTED MODEL].
PredictorBSEWaldp-ValueOR95% Confidence Interval (CI)
Primary0.0280.8880.001p = 0.9751.0280.180–5.860
Secondary–0.7320.3514.354p = 0.037 *0.4810.242–0.957
Uneducated–0.6930.5161.800p = 0.1800.5000.182–1.376
Health insurance (no)–0.4100.2901.995p = 0.1580.6640.376–1.172
Residence (rural)–0.6070.3642.787p = 0.0950.5450.267–1.111
Retired–0.0160.3390.002p = 0.9620.9840.506–1.911
Unemployed0.9450.4414.593p = 0.032 *2.5741.084–6.110
Income 5000–9999 SAR–0.2220.3790.342p = 0.5590.8010.381–1.684
Income 10,000–14,999 SAR–0.1340.3630.137p = 0.7110.8740.429–1.782
* p < 0.05 is considered significant. OR—odds ratio; CI—confidence interval; B value—beta value.
Table 7. Awareness of prostate cancer screening among study participants.
Table 7. Awareness of prostate cancer screening among study participants.
Awareness of PCa Screening QuestionsCategoryNumber (%)
Do you know some kinds of examination for cancer detection?Digital rectal examination only149 (37.34)
Prostate-specific antigen only74 (18.54)
DRE and prostate-specific antigen (PSA)1 (0.25)
Ultrasound58 (14.53)
Do not know117 (29.32)
Can early screening increase survival rates?Yes307 (76.94)
No92 (23.05)
Have you ever undergone a prostate-specific antigen (PSA) test?Yes177 (44.36)
No197 (49.37)
Do not remember145 (36.34)
When was the last time you underwent a prostate-specific antigen (PSA) test?Between one to two years44 (11.02)
Less than one year ago95 (23.80)
Never205 (51.37)
Over three years ago38 (9.52)
Awareness regarding treatmentDrugs/chemotherapy119 (29.82)
Surgery82 (20.55)
Radiation62 (15.53)
Herbal medication40 (10.02)
None of the above96 (24.06)
Should only men with urinary symptoms be screened?Yes164 (41.10)
No186 (46.61)
Do not know145 (36.34)
How important is it to have regular prostate examinations?Does not matter39 (9.77)
Important284 (71.17)
Little or not important at all76 (19.04)
Have you ever conducted a prostate exam?Yes156 (39.09)
No172 (43.10)
Do not remember145 (36.34)
If so, why was the prostate examination requested?Cancer case in the family26 (16.66)
Presented symptoms29 (18.58)
Prevention78 (50)
Participant requested the examination23 (14.74)
Table 8. Logistic regression results for PSA test taken versus sociodemographic variables.
Table 8. Logistic regression results for PSA test taken versus sociodemographic variables.
PredictorCategoryBStd. ErrorWaldp ValueOR95% Confidence Interval (CI)
Intercept −1.5750.35619.583p < 0.001 *
Age rangeAbove 60 years−0.5900.4891.453p = 0.2280.5550.213–1.447
51–60 years0.0900.3350.073p = 0.7881.0950.567–2.111
40–50 yearsReference
Marital statusNo−1.2940.6054.571p = 0.033 *0.2740.084–0.898
YesReference
Personal history of prostate problemsYes1.4130.29722.656p < 0.001*4.1072.296–7.348
NoReference
Health insuranceNo−0.8480.3127.374p = 0.0070.4280.232–0.790
YesReference
Education levelPrimary−0.2710.7840.119p = 0.7300.7630.164–3.549
Secondary−0.0430.3450.016p = 0.9010.9580.487–1.885
Other (uneducated)0.7570.5282.055p = 0.1522.1320.757–6.005
UniversityReference
ResidenceRural0.1720.3850.199p = 0.6561.1870.558–2.524
CityReference
OccupationRetired−0.1010.3640.077p = 0.7810.9040.442–1.846
Unemployed0.5880.3892.282p = 0.1311.8000.840–3.859
EmployedReference
Family history of prostate problemsMother’s relative1.3950.4489.688p = 0.002 *4.0331.676–9.707
From father0.5640.2794.081p = 0.043 *1.7581.017–3.040
Not knownReference
Monthly family income5000–9999 SAR0.2600.3440.570p = 0.4501.2970.661–2.546
10,000–14,999 SAR0.3520.3181.223p = 0.2691.4220.762–2.652
Above 15,000 SARReference
The dependent variable was binary (“Yes” = 1, “No” = 0), and all independent variables were categorical. The reference category for the outcome was “No”. * p < 0.05 is considered significant. OR—odds ratio; CI—confidence interval; B value—beta value.
Table 9. Logistic regression analysis of variables associated with awareness of prostate cancer screening among study participants.
Table 9. Logistic regression analysis of variables associated with awareness of prostate cancer screening among study participants.
Independent VariablesGroupsB ValueStd. ErrorWaldp ValueOR95% Confidence Interval (CI)
Intercept−0.8430.3316.500p = 0.011
Age rangesAbove 60 years−0.0280.4670.004p = 0.9530.9730.389–2.431
51–60 years0.2320.3250.511p = 0.4751.2620.667–2.387
40–50 yearsReference
Marital statusNo0.4610.4311.147p = 0.2841.5860.682–3.688
YesReference
Personal history of prostate problemsYes1.5670.28829.684p < 0.001 *4.7912.727–8.418
NoReference
Health insuranceYes1.0250.29212.334p < 0.001 *2.7861.573–4.935
NoReference
Level of educationPrimary level0.0710.7630.009p = 0.9261.0730.241–4.790
Secondary level−0.0400.3330.015p = 0.9030.9600.501–1.843
Other (uneducated)0.4830.5100.897p = 0.3441.6210.597–4.405
University levelReference
ResidenceRural−0.4590.3751.499p = 0.2210.6320.303–1.317
CityReference
OccupationRetired−0.5890.3612.661p = 0.1030.5550.273–1.126
Unemployed−0.2430.3760.417p = 0.5180.7840.375–1.640
EmployedReference
Family history of prostate problemsMothers relative0.7930.4373.289p = 0.0702.2100.938–5.204
From father0.5040.2683.535p = 0.0601.6560.979–2.800
Not knownReference
Monthly family income5000 to 9999 SAR0.1670.3260.262p = 0.6091.1820.624–2.238
10,000 to 14,999 SAR0.0640.3080.043p = 0.8361.0660.582–1.951
Above 15,000 SARReference
In all the independent variables, the last group is the reference category against which the OR is computed. * p < 0.05 is considered significant. OR—odds ratio; CI—confidence interval; B value—beta value.
Table 10. Logistic regression analysis of variables associated with awareness of prostate cancer screening among men without a personal history of prostate problems.
Table 10. Logistic regression analysis of variables associated with awareness of prostate cancer screening among men without a personal history of prostate problems.
Independent VariablesGroupsB ValueStd. ErrorWaldp ValueOR95% Confidence Interval (CI)
Intercept−1.9461.2122.579p = 0.108
Age ranges40–50 years0.6020.8460.505p = 0.4771.8250.347–9.590
51–60 years0.2750.8040.117p = 0.7321.3170.272–6.369
Above 60 yearsReference
Marital statusYes−0.9930.5103.790p = 0.0520.3700.136–1.007
NoReference
Health insuranceYes0.8280.4104.082p = 0.043 *2.2881.025–5.109
NoReference
Level of educationUp to secondary level−0.6050.8920.460p = 0.4980.5460.095–3.137
University level−0.7090.8900.635p = 0.4260.4920.086–2.818
Other (uneducated)Reference
ResidenceRural−0.1670.5730.085p = 0.7710.8460.275–2.602
CityReference
OccupationEmployed0.7740.7461.078p = 0.2992.1690.503–9.353
Unemployed1.7640.7545.476p = 0.019 *5.8341.332–25.552
RetiredReference
Family history of prostate problemsMother’s relative0.9830.9411.091p = 0.2962.6730.422–16.917
From father0.9110.4364.371p = 0.037 *2.4881.059–5.847
Not knownReference
Monthly family income5000 to 9999 SAR−0.1540.5480.078p = 0.7790.8580.293–2.511
10,000 to 14,999 SAR0.6610.4891.828p = 0.1761.9360.743–5.048
Above 15,000 SARReference
In all the independent variables, the last group is the reference category against which the OR is computed. * p < 0.05 is considered significant. OR—odds ratio; CI—confidence interval; B value—beta value. In educational qualification, cases of primary level education were not found for awareness—good category. Due to computational problems, this group was combined with secondary education and renamed as up to secondary level.
Table 11. Barriers to screening reported by the study population.
Table 11. Barriers to screening reported by the study population.
Barriers to ScreeningStrongly Disagree Number (%)Disagree Number (%)Agree Number (%)Strongly Agree Number (%)
Unable to afford.78 (19.54)92 (23.05)116 (29.07)113 (28.32)
In my opinion, I am in good health.27 (6.76)95 (23.80)201 (50.37)76 (19.04)
I am not sure where to go to get screened.32 (8.02)104 (26.06)171 (42.85)92 (23.05)
Have no faith that it will stop prostate cancer (PCa).83 (20.80)119 (29.82)108 (27.06)89 (22.30)
I am worried that during screening they will identify a problem.52 (13.03)77 (19.29)173 (43.35)97 (24.31)
I am scared it could affect my sexual health.47 (11.77)111 (27.81)161 (40.35)80 (20.05)
Participant screening is uncomfortable.58 (14.53)104 (26.06)154 (38.59)83 (20.80)
Think digital rectal exam (DRE) is harmful or embarrassing.49 (12.28)117 (29.32)156 (39.59)77 (19.29)
Prostate cancer (PCa) screening is time-consuming.42 (10.52)119 (29.82)157 (39.34)81 (20.30)
Think that PCa is not a serious illness.80 (20.05)115 (28.82)112 (28.07)92 (23.05)
Table 12. ANOVA and t-tests for variables versus barriers to prostate cancer screening.
Table 12. ANOVA and t-tests for variables versus barriers to prostate cancer screening.
VariablesGroupsBarriers ScoreF-Valuet-Valuep-Value
MeanS.D.Number
Age ranges40–50 years24.936.1214811.449---p < 0.001 *
51–60 years28.036.29145
Above 60 years27.424.66106
Marital statusYes26.835.97363---1.194p = 0.233
No25.586.1136
Personal history of prostate problemsYes28.265.94222---6.011p < 0.001 *
No24.795.48177
Health insuranceYes27.715.98272---4.998p < 0.001 *
No24.595.43127
Level of educationPrimary level26.754.11122.608---p = 0.051
Secondary level286.3281
University level26.086.07245
Other (uneducated)27.575.1861
ResidenceRural26.845.4117---0.254p = 0.800
City26.676.22282
OccupationEmployed25.836.71803.668---p = 0.026
Unemployed27.535.37122
Retired27.345.0997
Family history of prostate problemsMothers relative29.587.084017.407---p < 0.001 *
From father27.855.11184
Not known24.886.06175
Monthly family income5000 to 9999 SAR27.515.631305.148---p = 0.006 *
10,000 to 14,999 SAR27.166.15153
Above 15,000 SAR25.255.94116
Have you undergone a prostate specific antigen (PSA) test?Yes28.576.07177---5.733p < 0.001 *
No25.245.50222
S.D.—standard deviation; * p < 0.05 significance; ANOVA—analysis of variance.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Kandasamy, G.; Orayj, K.; Asiri, Y.I.; Shorog, E.; Alshahrani, A.M.; Alenazi, H.A. Public Awareness and Knowledge of Prostate Cancer Screening: A Community Study in Saudi Arabia. Healthcare 2025, 13, 1962. https://doi.org/10.3390/healthcare13161962

AMA Style

Kandasamy G, Orayj K, Asiri YI, Shorog E, Alshahrani AM, Alenazi HA. Public Awareness and Knowledge of Prostate Cancer Screening: A Community Study in Saudi Arabia. Healthcare. 2025; 13(16):1962. https://doi.org/10.3390/healthcare13161962

Chicago/Turabian Style

Kandasamy, Geetha, Khalid Orayj, Yahya I. Asiri, Eman Shorog, Asma M. Alshahrani, and Hebah Abdullah Alenazi. 2025. "Public Awareness and Knowledge of Prostate Cancer Screening: A Community Study in Saudi Arabia" Healthcare 13, no. 16: 1962. https://doi.org/10.3390/healthcare13161962

APA Style

Kandasamy, G., Orayj, K., Asiri, Y. I., Shorog, E., Alshahrani, A. M., & Alenazi, H. A. (2025). Public Awareness and Knowledge of Prostate Cancer Screening: A Community Study in Saudi Arabia. Healthcare, 13(16), 1962. https://doi.org/10.3390/healthcare13161962

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Article metric data becomes available approximately 24 hours after publication online.
Back to TopTop